⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

January 27, 2026Genes & Genomics

Epitranscriptomic regulation of NVP-BEZ235 resistance in ccRCC via the YTHDF3-SYNM regulatory pathway

Ruiang Wang Cheng Lu Erchang Shen Xi Zhang Xinchi Xu Xiaoyang Cao Tian Rao Xiaohan Ren Yiyang Liu Chen Xu Xiaoxiang Wang

View at Publisher

Ask AI

Bookmark

Share

Key Points

Resistance to NVP-BEZ235 in ccRCC is linked to the YTHDF3-SYNM regulatory pathway, revealing a novel mechanism.
Key evidence shows that altered activity of YTHDF3 significantly influences SYNM expression and treatment outcomes.
Analysis of transcriptomic profiles highlights the crucial role of epitranscriptomic changes in drug resistance mechanisms.
Findings suggest that understanding this regulatory pathway may enable the development of targeted therapies against drug resistance.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Observational analysis reveals epitranscriptomic regulation of NVP-BEZ235 resistance in ccRCC, suggesting new therapeutic targets.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/69a75abfc6e9836116a20f83 https://doi.org/10.1007/s13258-026-01737-z

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Renal Cell Cancer – Insights in Drug Resistance MechanismsReview · 2023 · 64 citations
2BEZ235-Mediated PI3K/mTOR dual inhibition improves ovarian follicle survival in a preclinical modelOriginal Research · 2025 · 2 citations
3Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenograftsEarly-Phase Clinical Trial · 2009 · 124 citations
4A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell CarcinomaEarly-Phase Clinical Trial · 2016 · 100 citations
5Dual Inhibition of PI3Kα and mTOR as an Alternative Treatment for Kaposi's SarcomaOriginal Research · 2008 · 56 citations

Inactivation of the von Hippel–Lindau ( <i>VHL</i> ) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a <i>VHL</i> ‐independent pathway in clear cell renal tumourigenesis1998
<scp>YTHDF3</scp> phase separation regulates <scp>HSPA13</scp>‐dependent clear cell renal cell carcinoma development and immune evasion2024
RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition2018
Complete chloroplast-based analysis reveals the emergence of candidate new species and revised divergence time in VincetoxicumGenes & Genomics · 2026
ROBO1 is required for postnatal growth and survivalGenes & Genomics · 2026

More from Genes & Genomics

More from Soochow University

More from Nanjing Medical University

More from Yangzhou University

More from First Affiliated Hospital of Soochow University